Which model for propofol TCI in children

Area of Science:

• Anesthesiology
• Pharmacokinetics
• Pharmacodynamics

Background:

• Total intravenous anesthesia (TIVA) with propofol offers advantages for pediatric anesthesia.
• Existing pharmacokinetic (PK) models for pediatric TIVA often lack precision due to limited covariates and high variability.
• Pharmacodynamic (PD) parameters and integrated PKPD models for pediatric propofol anesthesia are not yet established.

Purpose of the Study:

• To address the need for validated pharmacokinetic and pharmacodynamic (PKPD) models for propofol in pediatric anesthesia.
• To explore the adaptation of adult models, such as the Schnider model, for pediatric use.
• To investigate the importance of physiological covariates in pediatric PKPD modeling.

Main Methods:

• Review of existing 3-compartment PK models for propofol in children.
• Discussion of the limitations of weight-only covariates in pediatric PK models.
• Consideration of adapting adult PKPD models (e.g., Schnider) with multiple covariates for children over 5 years.
• Emphasis on incorporating physiological factors like age and size for improved metabolic process description.

Main Results:

• Current pediatric PK models for propofol have limitations, including large distribution volumes and significant interindividual variability.
• The Schnider model, with its inclusion of multiple covariates, shows potential for improved accuracy in describing propofol PKPD in older children.
• Physiological covariates are essential for accurately modeling metabolic processes during pediatric growth and maturation.

Conclusions:

• Pediatric TIVA with propofol requires tailored PKPD models that account for growth and maturation.
• Adapting adult models like Schnider's may offer a more robust approach for children over 5 years.
• Utilizing pharmacodynamic feedback, such as the bispectral index, can help manage interindividual variability in pediatric propofol anesthesia.